CN Respiratory Solutions Ltd, a UK-based medical technology company, has recently been granted a UK patent for their innovative respiratory technology. This new technology allows for nebulized medication and controlled oxygen delivery to be administered together through a single treatment device.
The patent, GB2642565, describes a unique fluid-mixing connector that combines a nebuliser with a Venturi oxygen-delivery device. This enables both therapies to be delivered concurrently, addressing a common challenge in respiratory care. The technology is designed to work with existing respiratory equipment, making it easily accessible for healthcare professionals.
CN Respiratory Solutions has been working in partnership with a reputable medical device manufacturer to progress the technology towards commercialization. Ian Bullock, Managing Director of CN Respiratory Solutions, expressed excitement over the patent grant, stating that it is a significant milestone for the company. He also emphasized the practicality of the technology in addressing the risk of hypercapnia in COPD patients, which is currently difficult to manage with existing equipment.
The company believes that their technology has potential applications in both acute and emergency respiratory care. The current product is a low-cost, single-use device that is suitable for use in all healthcare settings, including low and middle-income countries. This is important, as chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, with the majority of deaths occurring in these countries.
Nebulizers are a widely used method of delivering inhaled medication for various respiratory conditions, and the global market is expected to continue growing. CN Respiratory Solutions’ technology will primarily target hospitals, where patients often require repeated nebulizer treatments and are at risk of struggling with hypercapnia.
The patented technology has been designed to complement existing treatment regimens, allowing for rapid commercialization and development. This is a significant advantage, as the potential market for this technology is estimated to be in the tens of millions. CN Respiratory Solutions hopes to make a positive impact in respiratory care with their innovative technology.
About CN Respiratory Solutions Ltd:
CN Respiratory Solutions Ltd is a UK-based medical technology company that specializes in respiratory care. The company’s principal technology, protected by UK Patent GB2642565, is a fluid mixing device that has been granted on 26 August 2026. The inventor of this technology is Ian Bullock, the company’s Managing Director.
Editor’s Note:
Chronic obstructive pulmonary disease (COPD) is a major health concern, causing an estimated 3.4 million deaths in 2023, according to the World Health Organization. The majority of these deaths occur in low and middle-income countries, highlighting the importance of accessible and affordable respiratory care.
Distributed by https://pressat.co.uk/
